Garching / Munich, Germany, December 13, 2024 – ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced that its CEO, Dr. Andrew Cavey, and CFO, Dr. Klaus Maleck, will attend the 43^rd Annual J.P. Morgan Healthcare Conference in San Francisco. Dr. Cavey will give a company presentation on Monday, January 13, 2025, at 11:30 am PST in the Mission Bay Room (32nd Floor) at The Westin St. Francis.

For further information, contact:

Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email:

Corporate Communications
Kathleen Noonan / Julia Westermeir
Phone: +49 89 329 8986 1500
Email:

ITM Isotope Technologies Munich SE
ITM is a leading radiopharmaceutical biotech company committed to developing next-generation radiomolecular precision therapeutics and diagnostics for difficult-to-treat cancers. We are dedicated to serving the needs of cancer patients, clinicians, and partners through excellence in development, production, and global supply. Driven by improved patient outcomes, ITM is advancing a broad precision oncology pipeline, including multiple phase III studies, combining high-quality radioisotopes with various targeting molecules. Leveraging two decades of radiopharmaceutical expertise, a central industry role, and a global network, ITM aims to deliver more effective targeted therapies to enhance clinical results and quality of life.

Attachment